betonthenews Posted - 1 day ago

$OMER Seems to me GD wants Q1 earnings report and CC on May 15, one news for sure is 906 abstract will be available online on May 14, 2024 (16:00 CEST).

WinstonWolfff Posted - 1 day ago

$OMER What are we watching the last two days? In the recent past, we have seen shorts and MM's throttle the price by aggressively shorting the stock a few cents below the other offers. It's relentless and effective. When they pull off, the price increase is immediate and sustained for several days. When they resume the shorting at a higher level it's much more intense and the price immediately heads back down hard. During these moves, everyone watches volume. Two days ago they stepped back from shorting and we immediately surged on low volume. Let's see what happens this time.....is it different, or the same trend?

costrexx Posted - 1 day ago

$OMER I wonder who made this list up. It’s kind of funny and random https://www.sofi.com/learn/content/ipos-that-failed/

Shahr_ Posted - 1 day ago

$OMER what’s going on AH?

izacmann Posted - 1 day ago

$OMER up $1 this week?

applejack123 Posted - 1 day ago

$OMER - I’m usually posting negatives here but I’m pleased to see a little rebound from $3 over the past few days. Can we keep it up until if & when the BLA is resubmitted????

DBS25 Posted - 2 days ago

$OMER survived the R2k rebalance this time?

ipdamages Posted - 2 days ago

$OMER I'm more than happy to be up 10%, even if it is just the market and XBI (with a multiplier). It was a big part of what drove us down, so we might as well benefit when it comes back. Now back to your regularly scheduled episode of The Waiting Game.

Rjsmall Posted - 3 days ago

$OMER and in other news, TGTX sitting at $2.5mmm market cap

SteadyasSheGoes Posted - 04/30/24

$OMER Took me some time to digest the 4 million special bonus and the 1 million annual bonus paid Greg. I understand that it is for 2022 performance which included the company saving Omridia deal. As long as the 2023 bonus ( paid this year) reflects the failed phase three trial and the delays in TA-TMA approval, I guess it makes sense. Wont know for another 12 months.

Abaco24 Posted - 04/30/24

$OMER And so the "shit show" continues. Woke up to this BS after not reading for a week.....

Ernsse Posted - 04/30/24

$OMER Key take-aways for me from last nights release of the 2023 Annual Report and the Invitation to the Shareholder Meeting: 1) Confirmation that preliminary data from the ongoing OMS906 trials in PNH is at least as good as data from Iptacopan and others. "Two OMS906 Phase 2 clinical trials in PNH – one in treatment-naïve patients and the other in patients with a suboptimal response to ravulizumab – are fully enrolled and each has reported data at least as strong as any other AP- targeting agent on the market or in development." 2) Data from the 136 compassionate use cases in TA-TMA as already mentioned in an earlier post from @betonthenews 3) GD was paid a $4 million special cash bonus in 2023 for his role in securing OMIDRIA related payments. Bit hefty.... 4) Language in the Annual Report around TA-TMA BLA resubmission which could be viewed as a negative but actually was almost identical in the 2022 Annual Report. I will post the sentence in an answer to this post.

ipdamages Posted - 04/29/24

$OMER Today the notices came out about option issuances for Peter C., Mike J., and Greg: all priced in the low 3s. I commend management for two things related to this. 1. They implemented the buyback and have actively bought shares since November, which pushed the price into the 3s as of the time when the options issued. If the company hadn't instituted the buyback, those options would have probably been in the 1s, or possibly even lower. That benefits all of us shareholders, other than management. Without the buyback, there was the potential to give management a huge chunk of the company and its future value, through options. 2. The amount of the shares bought back more than covers all of the options issued, so even after these options, we are net antidilutive with the buyback. I have worked on many matters involving claims of management acting in breach of their fiduciary duty to shareholders. In contrast, this is a fine example of management creatively working for us and our interests.

rongside Posted - 04/29/24

$OMER "We continue to engage in discussions with potential partners as well as with representatives of the U.S. government regarding potential opportunities to obtain funding and advance development of our potential diagnostic and/or therapeutic product candidates for COVID-19, PASC or other infectious diseases." Watch this space.

ipdamages Posted - 04/29/24

$OMER Uh oh. 2.95 after hours. Was there a leak?

applejack123 Posted - 04/29/24

$OMER - here’s the most honest and forthright statement in the shareholder letter: “……demonstrates possession of the foresight and resilience needed to navigate setbacks…..” God knows, he’s had a lot of practice!!!

applejack123 Posted - 04/29/24

$OMER - 725,000 share options for a CEO who has delivered BUTKUS to his shareholders?????? A termination letter would be more appropriate!!!

betonthenews Posted - 04/29/24

$OMER From today's An annual report: "On the TA-TMA front, analysis of 136 patients in our Narsoplimab expanded access program shows strong overall survival (median 461 days following TMA diagnosis) similar to that of our pivotal clinical trial. Of those 136 adult and pediatric patients, 53 had failed or stopped previous treatment regimens with one or more of eculizumab, ravulizumab, defibrotid e and/or pegcetacoplan yet, with narsoplimab, 49% achieved 1-year survival from date of TMA diagnosis and 64% reached 1-year survival from date of transplant. The drug is saving lives. With over 600-subject exposure and no observed safety signal of concern, the benefit-risk profile is clearly favorable. Intera ctions with FDA regarding resubmission of our BLA are ongoing and we remain committed to achieving approval of narsoplimab in TA-TMA." On paper, reads and sounds great, but can GD dilver this time? https://investor.omeros.com/static-files/ad53d338-73cc-45e2-b005-27e4463685bf

izacmann Posted - 04/29/24

$OMER hello?

Rjsmall Posted - 04/29/24

$OMER so, May?

Rjsmall Posted - 04/26/24

$OMER anyone see the IBRX action today👀 soon…

TomMac64 Posted - 04/26/24

$OMER Did you guys see IBRX today they had a conference call and the ceo was so transparent unlike Greg when he screwed me in NARSOP !

betonthenews Posted - 04/25/24

$OMER Very unfortunate, the Russell rank day will fall on Tuesday, April 30, next Tuesday, and OMER may be deleted from Russel index again which may force few millions sell off in short term, if GD is confident of TMA approval, a very good chance to buy back few million shares low at once, let's see what happens.

applejack123 Posted - 04/25/24

$OMER - Now under $3. Delays and lack of status updates have been GD’s (and shareholder’s) demise. WORST CEO EVER!!

WinstonWolfff Posted - 04/25/24

$OMER Buying what is available below 3.

LongOmer Posted - 04/24/24

$OMER A chance to get a 50% gain from buying OMER between $3.00 and #3.10 this week. If not May, then in June the SP will likely be at $4.50 and over. This summer should see the SP run to $6.00++, I believe.

Falsee Posted - 04/24/24

$OMER another mother fucking buying fucking opportunity fucking fuck

RahaBoss Posted - 04/24/24

$OMER Bought a small position this morning at $3.04 for a swing trade.

applejack123 Posted - 04/24/24

$OMER - I posted this over a week ago without a single response: $OMER - beside Mismanagement, can anyone think of the reason(s) why the BLA has not been resubmitted???? They received feedback from the FDA and according to Dr.D. has met all the criteria! Anyone??????

Rjsmall Posted - 04/24/24

$OMER greggy really drumming up interest, real volume barn burner today at <100k traded